MukhtarE,AdhamiVM,MukhtarH, 2014.Targeting microtubules by natural agents for cancer therapy,Mol Cancer Ther 13 275 -84
ChandrasekaranG,TatraiP,GergelyF, 2015.Hitting the brakes: targeting microtubule motors in cancer,Br J Cancer 113 693 -8
PanicG,DuthalerU,SpeichB,KeiserJ, 2014.Repurposing drugs for the treatment and control of helminth infections,Int J Parasitol Drugs Drug Resist 4 185 -200
StantonRA,GernertKM,NettlesJH,AnejaR., 2011.Drugs that target dynamic microtubules: a new molecular perspective,Med Res Rev 31 443 -81
AleyasinH,KaruppagounderSS,KumarA,SleimanS,BassoM,MaT, 2015.Antihelminthic Benzimidazoles Are Novel HIF Activators That Prevent Oxidative Neuronal Death via Binding to Tubulin, 22 121 -34
DoudicanNA,ByronSA,PollockPM,OrlowSJ., 2013.XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts,Anticancer Drugs 24 181 -8
TanSK,JermakowiczA,MookhtiarAK,NemeroffCB,SchürerSC,AyadNG, 2018.Drug Repositioning in Glioblastoma: A Pathway Perspective,Front Pharmacol 9 218 -37
BaiRY,StaedtkeV,AprhysCM,GalliaGL,RigginsGJ, 2011.Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme,Neuro Oncol 13 974 -82
GrigoriadisA,MackayA,NoelE,WuPJ,NatrajanR,FrankumJ,Reis-FilhoJS,TuttA, 2012.Molecular characterisation of cell line models for triplenegative breast cancers,BMC 13 619 -33
HollidayDL, 2011.Speirs V. Choosing the right cell line for breast cancer research,Breast Cancer Res 13 215 -22
FlorentoL,MatiasR,TuañoE,SantiagoK,Dela CruzF, 2012.Tuazon A. Comparison of Cytotoxic Activity of Anticancer Drugs against Various Human Tumor Cell Lines Using In Vitro CellBased Approach,Int J Biomed Sci 8 76 -80
SliwkaL,WiktorskaK,SuchockiP,MilczarekM,MielczarekS,LubelskaK, 2016.The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions,PLoS One 11 e0155772 -
ParameeS,SookkheeS,SakonwasunC,Na TakuathungM,MungkornasawakulP,NimlamoolW, 2018.Anti-cancer effects of Kaempferia parviflora on ovarian cancer SKOV3 cells,BMC Complement Altern Med 18 178 -91
FoucquierJ,GuedjM., 2015.Analysis of drug combinations: current methodological landscape,Pharmacol Res Perspect 3 e00149 -
ReynoldsCP,MaurerBJ, 2005.Evaluating response to antineoplastic drug combinations in tissue culture models,Methods Mol Med 110 173 -83
BadisaRB,Darling-ReedSF,JosephP,CooperwoodJS,LatinwoLM,Goodman CB, 2009.,Selective Cytotoxic Activities of Two Novel Synthetic Drugs on Human Breast Carcinoma MCF-7 Cells. Anticancer Res 29 2993 -6
NygrenP,FryknasM,AgerupB,Larsson R, 2013.Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer,J Cancer Res Clin Oncol 139 2133 -40
CoyneCP,JonesT,Bear R. Gemcitabine-(C4- amide, 2013.-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with mebendazole against Chemotherapeutic-Resistant Mammary Adeno-carcinoma,J Clin Exp Oncol 2 100 -9
SpagnuoloPA,HuJ,HurrenR,WangX,GrondaM,SukhaiMA, 2010.The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma,Blood 115 4824 -33
PantziarkaP,BoucheG,MeheusL,SukhatmeV,Sukhatme VP, 2014.Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent,Ecancermedicalscience 8 443 -59
ZhangF,LiY,ZhangH,HuangE,GaoL,LuoW, 2017.Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC),Oncotarget 8 12968 -82